Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zydelig · 1 trial · 9 indications
The proportion of patients who discontinued the study due to Zydelig-related adverse events.
| Arm | Type | Description |
|---|---|---|
| Oral Zydelig 150 mg BID | EXPERIMENTAL | Zydelig given orally at 150 mg twice daily continuously on 28-day cycles starting 30 to 120 days after autologous stem cell transplantation for patients with indolent or transformed indolent B-cell NHL, for up to 1 year maintenance duration. Dose withhold/modification is allowed according to tolerability/toxicity. |
| Name | Type | Description |
|---|---|---|
| Zydelig | DRUG | Zydelig given at 150mg continuously in 28-day cycles |
Inclusion Criteria: 1. Histologically documented (by HPI or pathology report) iNHL as defined by follicular lymphoma (FL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma/Waldenstrom disease (LPL/WM) and small lymphocytic lymphoma (SLL) or tiNHL as defined by large B cell transformation of...
Zydelig is an investigational small molecule being studied for use in Non Hodgkin Lymphoma, specifically as maintenance therapy in B-cell Non Hodgkin's Lymphoma after autologous stem cell transplantation. It has been evaluated in a Phase 2 clinical trial for this purpose.
Zydelig is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD.
Zydelig is in Phase 2 clinical development for Non Hodgkin Lymphoma. It is an investigational drug and has not been approved by regulatory authorities for this indication.
Zydelig has been studied in one completed Phase 2 clinical trial, identified as NCT03133221, titled '1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation.' The trial enrolled 17 participants in the United States.
Zydelig is the brand name for idelalisib, a small molecule drug developed by Gilead Sciences. It is being investigated for use in Non Hodgkin Lymphoma, including conditions such as follicular lymphoma and marginal zone lymphoma.